{"slug": "towards-precision-psychiatry-initial-foundations-and-future-directions", "title": "Towards precision psychiatry: initial foundations and future directions", "summary": "Precision psychiatry, which uses biomarkers such as electroencephalography, functional magnetic resonance imaging, and peripheral biomarkers to align treatments with neural biology, could refine clinical trial design and improve outcomes in psychiatric drug discovery, according to a Perspective in Nature Reviews Drug Discovery. Proof-of-concept successes in postpartum depression and schizophrenia highlight the potential of stratified trials, though regulatory, commercial, and clinical considerations remain for integrating scalable biomarkers into drug development.", "body_md": "## Abstract\n\nPsychiatric disorders carry a major public health burden, yet advances in treatment have been slow to emerge, partly owing to reliance on traditional symptom-based diagnostic frameworks. In this Perspective, we explore the emerging paradigm of precision psychiatry, which seeks to align therapeutic development with underlying neural biology dysfunctions using biomarkers. Drawing lessons from the success of precision oncology and neurology, precision psychiatry utilizes patient-specific biological measures of brain function — such as electroencephalography, objective behavioural assessments, functional magnetic resonance imaging and peripheral biomarkers — to understand drugs’ effects on the brain, define indications and stratify patient populations for targeted intervention development. We discuss mechanistic approaches that focus on excitation–inhibition balance, reward and aversion circuits, hippocampal–prefrontal neuroplasticity, and processing of social cues, highlighting how these frameworks can elucidate drug mechanisms and predict treatment responses. Proof-of-concept examples, including predictors of response to standard-of-care treatments, and patient subgroup-driven successes in postpartum depression and schizophrenia, underscore the potential of stratified trials to reduce development risks and improve clinical outcomes. We address ongoing and future regulatory, commercial and clinical considerations for integrating scalable and reproducible biomarkers into drug development. Precision psychiatry thus represents a new strategy to refine clinical trial design and develop biology-defined treatments, which may help to overcome longstanding challenges in psychiatric drug discovery.\n\nThis is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41573-026-01509-0)\n\n## Access options\n\nAccess Nature and 54 other Nature Portfolio journals\n\nGet Nature+, our best-value online-access subscription\n\n27,99 € / 30 days\n\ncancel any time\n\nSubscribe to this journal\n\nReceive 12 print issues and online access\n\n269,00 € per year\n\nonly 22,42 € per issue\n\nBuy this article\n\n- Purchase on SpringerLink\n- Instant access to the full article PDF.\n\n39,95 €\n\nPrices may be subject to local taxes which are calculated during checkout\n\n### Similar content being viewed by others\n\n## References\n\nFDA-NIH Biomarker Working Group.\n\n*BEST**(** Biomarkers, EndpointS, and Other Tools) Resource*[online][https://www.ncbi.nlm.nih.gov/books/NBK326791/](https://www.ncbi.nlm.nih.gov/books/NBK326791/)(FDA, 2016).Rockoff, J. D. & Loftus, P. Bristol-Myers bucks trend toward precision medicine.\n\n*Wall Street Journal*[https://www.wsj.com/articles/bristol-bucks-trend-toward-precision-medicine-1457912801](https://www.wsj.com/articles/bristol-bucks-trend-toward-precision-medicine-1457912801)(13 Mar 2016).McGuigan, A. & Blair, H. A. Tofersen: a review in amyotrophic lateral sclerosis associated with\n\n*SOD1*mutations.*CNS Drugs***39**, 903–912 (2025).Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.\n\n*JAMA***330**, 512–527 (2023).van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease.\n\n*N. Engl. J. Med.***388**, 9–21 (2023).Schindler, S. E. et al. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease.\n\n*Nat. Rev. Neurol.***20**, 426–439 (2024).Etkin, A. & Mathalon, D. H. Bringing imaging biomarkers into clinical reality in psychiatry.\n\n*JAMA Psychiatry***81**, 1142–1147 (2024).Fusar-Poli, P. et al. Ethical considerations for precision psychiatry: a roadmap for research and clinical practice.\n\n*Eur. Neuropsychopharmacol.***63**, 17–34 (2022).Chekroud, A. M. et al. Illusory generalizability of clinical prediction models.\n\n*Science***383**, 164–167 (2024).Pizzagalli, D. A. et al. Pretreatment rostral anterior cingulate cortex theta activity in relation to symptom improvement in depression: a randomized clinical trial.\n\n*JAMA Psychiatry***75**, 547–554 (2018).Pizzagalli, D. A. Frontocingulate dysfunction in depression: toward biomarkers of treatment response.\n\n*Neuropsychopharmacology***36**, 183–206 (2011).Ip, C.-T. et al. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD.\n\n*J. Psychiatr. Res.***141**, 57–65 (2021).Voetterl, H. T. S. et al. Alpha peak frequency-based Brainmarker-I as a method to stratify to pharmacotherapy and brain stimulation treatments in depression.\n\n*Nat. Ment. Health***1**, 1023–1032 (2023).Voetterl, H. et al. Does 18 Hz deep TMS benefit a different subgroup of depressed patients relative to 10 Hz rTMS? The role of the individual alpha frequency.\n\n*Eur. Neuropsychopharmacol.***89**, 73–81 (2024).Voetterl, H. et al. Brainmarker-I differentially predicts remission to various attention-deficit/hyperactivity disorder treatments: a discovery, transfer, and blinded validation study.\n\n*Biol. Psychiatry Cogn. Neurosci. Neuroimaging***8**, 52–60 (2023).Schwartzmann, B. et al. Developing an electroencephalography-based model for predicting response to antidepressant medication.\n\n*JAMA Netw. Open***6**, e2336094 (2023).Wu, W. et al. An electroencephalographic signature predicts antidepressant response in major depression.\n\n*Nat. Biotechnol.***38**, 439–447 (2020).Zhang, Y. et al. Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography.\n\n*Nat. Biomed. Eng.*[https://doi.org/10.1038/s41551-020-00614-8](https://doi.org/10.1038/s41551-020-00614-8)(2020).Zhang, Y. et al. Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD.\n\n*Nat. Ment. Health***1**, 284–294 (2023).Elbau, I. G. et al. Functional connectivity mapping for rTMS target selection in depression.\n\n*Am. J. Psychiatry***180**, 230–240 (2023).Siddiqi, S. H., Weigand, A., Pascual-Leone, A. & Fox, M. D. Identification of personalized transcranial magnetic stimulation targets based on subgenual cingulate connectivity: an independent replication.\n\n*Biol. Psychiatry***90**, e55–e56 (2021).Weigand, A. et al. Prospective validation that subgenual connectivity predicts antidepressant efficacy of transcranial magnetic stimulation sites.\n\n*Biol. Psychiatry***84**, 28–37 (2018).Lynch, C. J. et al. Frontostriatal salience network expansion in individuals in depression.\n\n*Nature***633**, 624–633 (2024).López-Solà, C. et al. Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective.\n\n*Eur. Psychiatry***63**, e74 (2020).Nijdam, M. J., de Vries, G.-J., Gersons, B. P. R. & Olff, M. Response to psychotherapy for posttraumatic stress disorder: the role of pretreatment verbal memory performance.\n\n*J. Clin. Psychiatry***76**, e1023–e1028 (2015).Deligiannidis, K. M. et al. Zuranolone for the treatment of postpartum depression.\n\n*Am. J. Psychiatry***180**, 668–675 (2023).Clayton, A. H. et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 Trial.\n\n*Am. J. Psychiatry***180**, 676–684 (2023).Parikh, S. V. et al. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.\n\n*Neuropsychopharmacology***49**, 467–475 (2024).Wang, S. et al. Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis.\n\n*Front. Neurosci.***17**, 1332329 (2023).Winslow, M., White, E., Rose, S. J., Salzer, E. & Nemec, E. C. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.\n\n*Int. J. Clin. Pharm.***46**, 590–601 (2024).Batt, M. M., Duffy, K. A., Novick, A. M., Metcalf, C. A. & Epperson, C. N. Is postpartum depression different from depression occurring outside of the perinatal period? A review of the evidence.\n\n*Focus (Am. Psychiatr. Publ.)***18**, 106–119 (2020).Luo, W. et al. Discovery of a potential novel pharmacogenomic biomarker on\n\n*ANK3*gene for liafensine, a triple reuptake inhibitor for treatment-resistant depression.*Transl. Psychiatry*[https://doi.org/10.1038/s41398-026-04144-w](https://doi.org/10.1038/s41398-026-04144-w)(2026).Wang, G. et al. ANK3 as a novel genetic biomarker for liafensine in treatment-resistant depression: the ENLIGHTEN randomized clinical trial.\n\n*JAMA Psychiatry***82**, 1186–1194 (2025).Savitz, A. et al. Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study.\n\n*Int. J. Neuropsychopharmacol.***24**, 965–976 (2021).Mesens, S. et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.\n\n*Mol. Psychiatry*[https://doi.org/10.1038/s41380-024-02846-5](https://doi.org/10.1038/s41380-024-02846-5)(2025).Johnson & Johnson. Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes.\n\n*PR Newswire*[https://www.prnewswire.com/news-releases/johnson--johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes-302157980.html](http://www.prnewswire.com/news-releases/johnson--johnson-pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes-302157980.html)(2024).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT04533529](https://clinicaltrials.gov/study/NCT04533529)(2025).Hui, T. P. et al. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder.\n\n*Acta Psychiatr. Scand.***140**, 94–115 (2019).Ikeda, A. & Kato, T. Biological predictors of lithium response in bipolar disorder.\n\n*Psychiatry Clin. Neurosci.***57**, 243–250 (2003).Freund, T. F. & Buzsáki, G. Interneurons of the hippocampus.\n\n*Hippocampus***6**, 347–470 (1996).Marín, O. Parvalbumin interneuron deficits in schizophrenia.\n\n*Eur. Neuropsychopharmacol.***82**, 44–52 (2024).Gonzalez-Burgos, G. & Lewis, D. A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.\n\n*Schizophr. Bull.***38**, 950–957 (2012).Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia.\n\n*Nat. Rev. Neurosci.***6**, 312–324 (2005).Steullet, P. et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia.\n\n*Mol. Psychiatry***22**, 936–943 (2017).Lewis, D. A. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.\n\n*Brain Res. Rev.***31**, 270–276 (2000).Smeralda, C. L. et al. The role of parvalbumin interneuron dysfunction across neurodegenerative dementias.\n\n*Ageing Res. Rev.***101**, 102509 (2024).Yao, Y. & Li, Q. The role of parvalbumin interneurons in autism spectrum disorder.\n\n*J. Neurosci. Res.***102**, e25391 (2024).Cahalane, D. J., Charvet, C. J. & Finlay, B. L. Modeling local and cross-species neuron number variations in the cerebral cortex as arising from a common mechanism.\n\n*Proc. Natl Acad. Sci. USA***111**, 17642–17647 (2014).Umbricht, D. & Krljes, S. Mismatch negativity in schizophrenia: a meta-analysis.\n\n*Schizophr. Res.***76**, 1–23 (2005).Cabungcal, J.-H. et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia.\n\n*Neuron***83**, 1073–1084 (2014).Fagiolini, M. & Hensch, T. K. Inhibitory threshold for critical-period activation in primary visual cortex.\n\n*Nature***404**, 183–186 (2000).O’Donnell, P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia.\n\n*Eur. J. Neurosci.***35**, 1866–1870 (2012).Steullet, P. et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology?\n\n*Schizophr. Res.***176**, 41–51 (2016).Moran, L. V. & Hong, L. E. High vs low frequency neural oscillations in schizophrenia.\n\n*Schizophr. Bull.***37**, 659–663 (2011).Spencer, K. M. in\n\n*Neurophysiologic Biomarkers in Neuropsychiatric Disorders**:** Etiologic and Treatment Considerations*(eds Javitt, D. C. & McPartland, J. C.) 321–349 (Springer, 2024).Hong, L. E. et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.\n\n*Neuropsychopharmacology***35**, 632–640 (2010).Hong, L. E., Moran, L. V., Du, X., O’Donnell, P. & Summerfelt, A. Mismatch negativity and low frequency oscillations in schizophrenia families.\n\n*Clin. Neurophysiol.***123**, 1980–1988 (2012).O’Donnell, P. et al. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.\n\n*Neuropsychopharmacology***48**, 1052–1059 (2023).Cecchi, M. et al. Baseline mismatch negativity amplitude predicts direction and magnitude of ketamine effect in healthy volunteers: a disordinal effect.\n\n*Biol. Psychiatry*[https://doi.org/10.1016/j.biopsych.2026.03.1008](https://doi.org/10.1016/j.biopsych.2026.03.1008)(2026).Østergaard, F. G. et al. The aperiodic exponent of neural activity varies with vigilance state in mice and men.\n\n*PLoS ONE***19**, e0301406 (2024).Earl, R. J., Ford, T. C., Lum, J. A. G., Enticott, P. G. & Hill, A. T. Exploring aperiodic activity in first episode schizophrenia spectrum psychosis: a resting-state EEG analysis.\n\n*Brain Res.***1840**, 149052 (2024).McKeon, S. D. et al. Aperiodic EEG and 7T MRSI evidence for maturation of E/I balance supporting the development of working memory through adolescence.\n\n*Dev. Cogn. Neurosci.***66**, 101373 (2024).Gyurkovics, M., Clements, G. M., Low, K. A., Fabiani, M. & Gratton, G. Stimulus-induced changes in 1/f-like background activity in EEG.\n\n*J. Neurosci.***42**, 7144–7151 (2022).Khadimallah, I. et al. Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia.\n\n*Mol. Psychiatry***27**, 1192–1204 (2022).Kaul, I. et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial.\n\n*JAMA Psychiatry***81**, 749–756 (2024).Horan, W. P. et al. The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials.\n\n*Am. J. Psychiatry***182**, 297–306 (2024).Cotter, J., Barnett, J. H. & Granger, K. The use of cognitive screening in pharmacotherapy trials for cognitive impairment associated with schizophrenia.\n\n*Front. Psychiatry***10**, 648 (2019).Keefe, R. S. et al. Randomized, double-blind, placebo-controlled study of encenicline, an\n\n*α*7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia.*Neuropsychopharmacology***40**, 3053–3060 (2015).Kinon, B. J., Millen, B. A., Zhang, L. & McKinzie, D. L. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.\n\n*Biol. Psychiatry***78**, 754–762 (2015).Kantrowitz, J. T. et al. Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.\n\n*Neuropsychopharmacology***45**, 1842–1850 (2020).Terry-Lorenzo, R. T., Fan, R. H., Khin, N. A. & Singh, J. B. Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat.\n\n*Int. J. Neuropsychopharmacol.***28**, pyae066 (2025).Rosenbrock, H., Desch, M. & Wunderlich, G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.\n\n*Eur. Arch. Psychiatry Clin. Neurosci.***273**, 1557–1566 (2023).Schultheis, C. et al. Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a Phase II substudy of patients treated with iclepertin (BI 425809).\n\n*Transl. Psychiatry***12**, 329 (2022).Murthy, V. et al. INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia.\n\n*Schizophr. Res.***270**, 249–257 (2024).Stauffer, V. L. et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.\n\n*Schizophr. Res.***150**, 434–441 (2013).Uliana, D. L., Lisboa, J. R. F., Gomes, F. V. & Grace, A. A. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.\n\n*Biochem. Pharmacol.***228**, 116298 (2024).Gilleen, J. et al. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: a randomised controlled trial.\n\n*J. Psychopharmacol.***35**, 15–22 (2021).Ravindran, A. S. et al. 437. Identification of brain/behavior-based pro-cognitive pharmacodynamic effects for ALTO-101 in healthy volunteers: results from a randomized, double-blind phase 1 study.\n\n*Biol. Psychiatry***95**, S279 (2024).Retsa, C. et al. Treatment in early psychosis with\n\n*N*-acetyl-cysteine for 6 months improves low-level auditory processing: pilot study.*Schizophr. Res.***191**, 80–86 (2018).Auerbach, R. P., Pagliaccio, D. & Pizzagalli, D. A. Toward an improved understanding of anhedonia.\n\n*JAMA Psychiatry***76**, 571–573 (2019).Husain, M. & Roiser, J. P. Neuroscience of apathy and anhedonia: a transdiagnostic approach.\n\n*Nat. Rev. Neurosci.***19**, 470–484 (2018).Kelly, C. A., Freeman, K. B. & Schumacher, J. A. Treatment-resistant depression with anhedonia: integrating clinical and preclinical approaches to investigate distinct phenotypes.\n\n*Neurosci. Biobehav. Rev.***136**, 104578 (2022).Pizzagalli, D. A. Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation?\n\n*Am. J. Psychiatry***179**, 458–469 (2022).Serretti, A. Anhedonia and depressive disorders.\n\n*Clin. Psychopharmacol. Neurosci.***21**, 401–409 (2023).Cuthbert, B. N. Research Domain Criteria (RDoC): progress and potential.\n\n*Curr. Dir. Psychol. Sci.***31**, 107–114 (2022).Lambert, C. et al. Anhedonia in depression and schizophrenia: a transdiagnostic challenge.\n\n*CNS Neurosci. Ther.***24**, 615–623 (2018).Whitton, A. E. & Pizzagalli, D. A. in\n\n*Anhedonia: Preclinical, Translational, and Clinical Integration. Current Topics in Behavioral Neurosciences*, Vol. 58 (ed. Pizzagalli, D. A.) 111–127 (Springer, 2022).Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders.\n\n*Nat. Rev. Neurosci.***14**, 609–625 (2013).Oikonomidis, L. et al. A dimensional approach to modeling symptoms of neuropsychiatric disorders in the marmoset monkey.\n\n*Dev. Neurobiol.***77**, 328–353 (2017).Zhu, X. et al. Phenotypic and genetic associations between anhedonia and brain structure in UK Biobank.\n\n*Transl. Psychiatry***11**, 395 (2021).Pizzagalli, D. A. & Roberts, A. C. Prefrontal cortex and depression.\n\n*Neuropsychopharmacology***47**, 225–246 (2022).Cao, B. et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: a systematic review.\n\n*Prog. Neuro-Psychopharmacol. Biol. Psychiatry***92**, 109–117 (2019).Ressler, K. J. & Nemeroff, C. B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.\n\n*Depress. Anxiety***12**, 2–19 (2000).Klein, M. E., Grice, A. B., Sheth, S., Go, M. & Murrough, J. W. in\n\n*Anhedonia: Preclinical, Translational, and Clinical Integration. Current Topics in Behavioral Neurosciences,*Vol. 58 (ed. Pizzagalli, D. A.) 489–467 (Springer, 2022).Luca, A. et al. Anhedonia is associated with a specific depression profile and poor antidepressant response.\n\n*Int. J. Neuropsychopharmacol.***27**, pyae055 (2024).Chenu, F., El Mansari, M. & Blier, P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.\n\n*Neuropsychopharmacology***38**, 275–284 (2013).Di Giannantonio, M. & Martinotti, G. Anhedonia and major depression: the role of agomelatine.\n\n*Eur. Neuropsychopharmacol.***22**, S505–S510 (2012).Ang, Y.-S. et al. Pretreatment reward sensitivity and frontostriatal resting-state functional connectivity are associated with response to bupropion after sertraline nonresponse.\n\n*Biol. Psychiatry***88**, 657–667 (2020).Cooper, N. et al. Effects of a novel histamine 3 receptor (H3R) on positive emotion and reward processing: methods and preliminary data in an ongoing phase 2 proof-of-concept study.\n\n*Neurosci. Appl.***3**, 104729 (2024).Gupta, R. S., Light, G. A., Simmons, A. N., Harlé, K. M. & Stout, D. M. Sex moderates the effect of anhedonia on parietal alpha asymmetry.\n\n*J. Psychiatr. Res.***177**, 97–101 (2024).Umemoto, A. et al. Resting posterior alpha power and adolescent major depressive disorder.\n\n*J. Psychiatr. Res.***141**, 233–240 (2021).US FDA. Letter regarding intent to market\n\n[https://www.Accessdata.Fda.Gov/Cdrh_docs/Pdf22/K222101.Pdf](https://www.Accessdata.Fda.Gov/Cdrh_docs/Pdf22/K222101.Pdf)(2023).Singer, N. et al. Development and validation of an fMRI-informed EEG model of reward-related ventral striatum activation.\n\n*NeuroImage***276**, 120183 (2023).Whitton, A. E. et al. Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression.\n\n*Brain***143**, 701–710 (2020).Miller, A. H. Neuroendocrine and immune system interactions in stress and depression.\n\n*Psychiatr. Clin. N. Am.***21**, 443–463 (1998).Raison, C. L., Capuron, L. & Miller, A. H. Cytokines sing the blues: inflammation and the pathogenesis of depression.\n\n*Trends Immunol.***27**, 24–31 (2006).Felger, J. C. et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression.\n\n*Mol. Psychiatry***21**, 1358–1365 (2016).Sun, Y. et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease.\n\n*Brain Behav. Immun.***66**, 156–164 (2017).Bekhbat, M. et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.\n\n*Mol. Psychiatry***27**, 4113–4121 (2022).Costi, S. et al. Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia.\n\n*Transl. Psychiatry***11**, 565 (2021).Drevets, W. C., Wittenberg, G. M., Bullmore, E. T. & Manji, H. K. Immune targets for therapeutic development in depression: towards precision medicine.\n\n*Nat. Rev. Drug Discov.***21**, 224–244 (2022).Lee, Y. et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression.\n\n*Ther. Adv. Psychopharmacol.***8**, 337–348 (2018).Lucido, M. J. et al. Aiding and abetting anhedonia: impact of inflammation on the brain and pharmacological implications.\n\n*Pharmacol. Rev.***73**, 1084–1117 (2021).Nogo, D. et al. Examining the association between inflammation and motivational anhedonia in neuropsychiatric disorders: a systematic review.\n\n*Ann. Clin. Psychiatry***33**, 193–206 (2021).Treadway, M. T. et al. A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation.\n\n*Mol. Psychiatry***30**, 1407–1417 (2024).Rizk, M. M. et al. Immune-targeted therapies for depression: current evidence for antidepressant effects of monoclonal antibodies.\n\n*J. Clin. Psychiatry***85**, 23nr15243 (2024).Lally, N. et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.\n\n*Transl. Psychiatry***4**, e469 (2014).Lally, N. et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.\n\n*J. Psychopharmacol.***29**, 596–607 (2015).Nogo, D. et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.\n\n*Psychopharmacology***239**, 2011–2039 (2022).Rodrigues, N. B. et al. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian Rapid Treatment Center of Excellence.\n\n*J. Affect. Disord.***276**, 570–575 (2020).Price, R. B. et al. International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators.\n\n*Mol. Psychiatry***27**, 5096–5112 (2022).Jawad, M. Y. et al. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.\n\n*Neuropharmacology***223**, 109299 (2023).Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.\n\n*Nature***475**, 91–95 (2011).Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.\n\n*Science***329**, 959–964 (2010).McIntyre, R. S. & Jain, R. Glutamatergic modulators for major depression from theory to clinical use.\n\n*CNS Drugs***38**, 869–890 (2024).Liu, H. et al. Functional connectivity of the amygdala and the antidepressant and antisuicidal effects of repeated ketamine infusions in major depressive disorder.\n\n*Front. Neurosci.***17**, 1123797 (2023).Chen, M.-H. et al. Functional dysconnectivity of frontal cortex to striatum predicts ketamine infusion response in treatment-resistant depression.\n\n*Int. J. Neuropsychopharmacol.***23**, 791–798 (2020).Wong, S. et al. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: a systematic review and meta-analysis.\n\n*J. Affect. Disord.***356**, 684–698 (2024).Mague, S. D. et al. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats.\n\n*J. Pharmacol. Exp. Ther.***305**, 323–330 (2003).Wong, S. et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review.\n\n*J. Affect. Disord.***362**, 816–827 (2024).Krystal, A. D. et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia.\n\n*Nat. Med.***26**, 760–768 (2020).Hampsey, E., Jelen, L. & Young, A. H. Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder.\n\n*Expert Opin. Emerg. Drugs***29**, 193–204 (2024).Demyttenaere, K. Aticaprant, a kappa opioid receptor antagonist, and the recovered ‘interest and pleasure’ in the concept of major depressive disorder.\n\n*Eur. Arch. Psychiatry Clin. Neurosci.***275**, 1593–1597 (2025).Schmidt, M. E. et al. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.\n\n*Neuropsychopharmacology***49**, 1437–1447 (2024).Nestler, E. J. & Carlezon, W. A. The mesolimbic dopamine reward circuit in depression.\n\n*Biol. Psychiatry***59**, 1151–1159 (2006).Carlezon, W. A. & Krystal, A. D. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials.\n\n*Depress. Anxiety***33**, 895–906 (2016).Pizzagalli, D. A. et al. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS).\n\n*Neuropsychopharmacology***45**, 1656–1663 (2020).Ragguett, R.-M., Rong, C., Rosenblat, J. D., Ho, R. C. & McIntyre, R. S. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.\n\n*Expert Opin. Drug Metab. Toxicol.***14**, 475–482 (2018).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT05455684](https://clinicaltrials.gov/study/NCT05455684)(2025).Popova V. et al. (Poster Presentation) Results from the phase 3, double-blind, placebo-controlled VENTURA-1 and -2 studies of aticaprant, Adjunctive to Antidepressants, in Adults With Major Depressive Disorder with moderate-to-severe anhedonia. in\n\n*American Society of Clinical Psychopharmacology*(2025).Johnson & Johnson statement on VENTURA program.\n\n*Johnson & Johnson*[https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-ventura-program](https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-ventura-program)(2025).Mathew, S. et al. Navacaprant, a novel kappa opioid receptor antagonist for major depressive disorder: a randomized placebo-controlled phase 2 trial.\n\n*Biol. Psychiatry***95**, S10 (2024).Neumora Therapeutics reports data from KOASTAL-1 study of navacaprant in major depressive disorder.\n\n*GlobeNewswire*[https://www.globenewswire.com/news-release/2025/01/02/3003449/0/en/Neumora-Therapeutics-Reports-Data-from-KOASTAL-1-Study-of-Navacaprant-in-Major-Depressive-Disorder.html](https://www.globenewswire.com/news-release/2025/01/02/3003449/0/en/Neumora-Therapeutics-Reports-Data-from-KOASTAL-1-Study-of-Navacaprant-in-Major-Depressive-Disorder.html)(2025).Tundo, A., Filippis, R. & De Crescenzo, F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis.\n\n*Acta Psychiatr. Scand.***140**, 116–125 (2019).Halahakoon, D. C. et al. Reward-processing behavior in depressed participants relative to healthy volunteers: a systematic review and meta-analysis.\n\n*JAMA Psychiatry***77**, 1286–1295 (2020).Browning, M. et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK.\n\n*Lancet Psychiatry***12**, 579–589 (2025).Ventorp, F. et al. Preliminary evidence of efficacy and target engagement of pramipexole in anhedonic depression.\n\n*Psychiatr. Res. Clin. Pract.***4**, 42–47 (2022).Krishnan, V. et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions.\n\n*Cell***131**, 391–404 (2007).Friedman, A. K. et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism.\n\n*Nat. Commun.***7**, 11671 (2016).Costi, S., Han, M.-H. & Murrough, J. W. The potential of KCNQ potassium channel openers as novel antidepressants.\n\n*CNS Drugs***36**, 207–216 (2022).Meshkat, S. et al. The role of KCNQ channel activators in management of major depressive disorder.\n\n*J. Affect. Disord.***359**, 364–372 (2024).Tan, A. et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.\n\n*Mol. Psychiatry***25**, 1323–1333 (2020).Chowdhury, A. et al. Effects of the KCNQ (Kv7) channel opener ezogabine on resting-state functional connectivity of striatal brain reward regions, depression, and anhedonia in major depressive disorder: results from a randomized controlled trial.\n\n*Biol. Psychiatry***98**, 568–577 (2025).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT06419608](https://clinicaltrials.gov/study/NCT06419608)(2025).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT06419582](https://clinicaltrials.gov/study/NCT06419582)(2024).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT06775379](https://clinicaltrials.gov/study/NCT06775379)(2025).Ressler, K. J. et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits.\n\n*Nat. Rev. Neurol.***18**, 273–288 (2022).HMNC Brain Health announces phase 2 results from OLIVE Trial in major depressive disorder (MDD) with genetically guided precision approach.\n\n*GlobeNewswire*[https://www.globenewswire.com/news-release/2025/08/05/3127402/0/en/HMNC-Brain-Health-Announces-Phase-2-Results-from-OLIVE-Trial-in-Major-Depressive-Disorder-MDD-with-Genetically-Guided-Precision-Approach.html](https://www.globenewswire.com/news-release/2025/08/05/3127402/0/en/HMNC-Brain-Health-Announces-Phase-2-Results-from-OLIVE-Trial-in-Major-Depressive-Disorder-MDD-with-Genetically-Guided-Precision-Approach.html)(2025).O’Donnell, P., Etkin, A. & Manji, H. K. Brain neuroplasticity mechanisms in psychiatric illnesses and in the development of novel treatments.\n\n*Am. J. Psychiatry***183**, 98–107 (2026).Vaidya, V. A. & Duman, R. S. Depression – emerging insights from neurobiology.\n\n*Br. Med. Bull.***57**, 61–79 (2001).Chen, F. et al. Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects.\n\n*Brain Res.***1727**, 146546 (2020).Stockmeier, C. A. et al. Cellular changes in the postmortem hippocampus in major depression.\n\n*Biol. Psychiatry***56**, 640–650 (2004).Chang, L.-C. et al. A conserved BDNF, glutamate- and GABA-enriched gene module related to human depression identified by coexpression meta-analysis and DNA variant genome-wide association studies.\n\n*PLoS ONE***9**, e90980 (2014).Duric, V. et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects.\n\n*Int. J. Neuropsychopharmacol.***16**, 69–82 (2013).Feyissa, A. M., Chandran, A., Stockmeier, C. A. & Karolewicz, B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.\n\n*Prog. Neuro-Psychopharmacol. Biol. Psychiatry***33**, 70–75 (2009).Fuchsova, B., Alvarez Juliá, A., Rizavi, H. S., Frasch, A. C. & Pandey, G. N. Altered expression of neuroplasticity-related genes in the brain of depressed suicides.\n\n*Neuroscience***299**, 1–17 (2015).Kang, H. J. et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder.\n\n*Nat. Med.***18**, 1413–1417 (2012).Schmaal, L. et al. ENIGMA MDD: seven years of global neuroimaging studies of major depression through worldwide data sharing.\n\n*Transl. Psychiatry***10**, 172 (2020).Colle, R. et al. Smaller hippocampal volumes predict lower antidepressant response/remission rates in depressed patients: a meta-analysis.\n\n*World J. Biol. Psychiatry***19**, 360–367 (2018).Malykhin, N. V., Carter, R., Seres, P. & Coupland, N. J. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment.\n\n*J. Psychiatry Neurosci.***35**, 337–343 (2010).Phillips, J. L., Batten, L. A., Tremblay, P., Aldosary, F. & Blier, P. A. Prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression.\n\n*Int. J. Neuropsychopharmacol.***18**, pyv037 (2015).Saury, J.-M. & Emanuelson, I. Neuropsychological assessment of hippocampal integrity.\n\n*Appl. Neuropsychol. Adult***24**, 140–151 (2017).Burgess, N., Maguire, E. A. & O’Keefe, J. The human hippocampus and spatial and episodic memory.\n\n*Neuron***35**, 625–641 (2002).Grunwald, T. et al. Evidence relating human verbal memory to hippocampal\n\n*N*-methyl-d-aspartate receptors.*Proc. Natl Acad. Sci. USA***96**, 12085–12089 (1999).Bora, E., Harrison, B. J., Yücel, M. & Pantelis, C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis.\n\n*Psychol. Med.***43**, 2017–2026 (2013).Cullen, B. et al. Cognitive function in people with familial risk of depression.\n\n*JAMA Psychiatry***80**, 610 (2023).Parkinson, W. L., Rehman, Y., Rathbone, M. & Upadhye, S. Performances on individual neurocognitive tests by people experiencing a current major depression episode: a systematic review and meta-analysis.\n\n*J. Affect. Disord.***276**, 249–259 (2020).Lee, R. S. C., Hermens, D. F., Porter, M. A. & Redoblado-Hodge, M. A. A meta-analysis of cognitive deficits in first-episode major depressive disorder.\n\n*J. Affect. Disord.***140**, 113–124 (2012).Wagner, S., Müller, C., Helmreich, I., Huss, M. & Tadić, A. A meta-analysis of cognitive functions in children and adolescents with major depressive disorder.\n\n*Eur. Child Adolesc. Psychiatry***24**, 5–19 (2015).Hack, L. M. et al. A cognitive biotype of depression and symptoms, behavior measures, neural circuits, and differential treatment outcomes: a prespecified secondary analysis of a randomized clinical trial.\n\n*JAMA Netw. Open***6**, e2318411 (2023).Pu, S., Noda, T., Setoyama, S. & Nakagome, K. Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications.\n\n*Psychol. Med.***48**, 2717–2729 (2018).McIntyre, R. S. et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.\n\n*Depress. Anxiety***30**, 515–527 (2013).McIntyre, R. S. & Lee, Y. Cognition in major depressive disorder: a ‘systemically important functional index’ (SIFI).\n\n*Curr. Opin. Psychiatry***29**, 48–55 (2016).Woo, Y. S., Rosenblat, J. D., Kakar, R., Bahk, W.-M. & McIntyre, R. S. Cognitive deficits as a mediator of poor occupational function in remitted major depressive disorder patients.\n\n*Clin. Psychopharmacol. Neurosci.***14**, 1–16 (2016).Pan, Z. et al. Cognitive impairment in major depressive disorder.\n\n*CNS Spectr.***24**, 22–29 (2019).Sankar, A. et al. Association of neurocognitive function with psychiatric hospitalization and socio-demographic conditions in individuals with bipolar and major depressive disorders.\n\n*eClinicalMedicine***58**, 101927 (2023).Gualtieri, C. T. & Morgan, D. W. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials.\n\n*J. Clin. Psychiatry***69**, 1122–1130 (2008).Asch, R. H., Abdallah, C. G., Carson, R. E. & Esterlis, I. Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.\n\n*Neuropsychopharmacology***50**, 153–163 (2025).Kaneko, N. et al. Neuroplasticity of the left dorsolateral prefrontal cortex in patients with treatment-resistant depression as indexed with paired associative stimulation: a TMS–EEG study.\n\n*Cereb. Cortex***34**, bhad515 (2024).Herzberg, M. P., Nielsen, A. N., Luby, J. & Sylvester, C. M. Measuring neuroplasticity in human development: the potential to inform the type and timing of mental health interventions.\n\n*Neuropsychopharmacology***50**, 124–136 (2025).Neurocrine Biosciences reports positive phase 2 data for NBI-1065845 in adults with major depressive disorder.\n\n*PR Newswire*[https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-in-adults-with-major-depressive-disorder-302123889.html](https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-positive-phase-2-data-for-nbi-1065845-in-adults-with-major-depressive-disorder-302123889.html)(2024).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT06547489](https://clinicaltrials.gov/study/NCT06547489)(2026).Preskorn, S. et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.\n\n*J. Psychiatr. Pract.***21**, 140–149 (2015).Allergan announces phase 3 results for rapastinel as an adjunctive treatment of major depressive disorder (MDD).\n\n*PR Newswire*[https://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html](https://www.prnewswire.com/news-releases/allergan-announces-phase-3-results-for-rapastinel-as-an-adjunctive-treatment-of-major-depressive-disorder-mdd-300808044.html)(2019).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT05066672](https://clinicaltrials.gov/study/NCT05066672)(2023).Sengupta, S. et al. Discovery of NV-5138, the first selective Brain mTORC1 activator.\n\n*Sci. Rep.***9**, 4107 (2019).Fitzsimmons, S. M. D. D., Oostra, E., Postma, T. S., Van Der Werf, Y. D. & Van Den Heuvel, O. A. Repetitive transcranial magnetic stimulation–induced neuroplasticity and the treatment of psychiatric disorders: state of the evidence and future opportunities.\n\n*Biol. Psychiatry***95**, 592–600 (2024).Cash, R. F. H., Cocchi, L., Lv, J., Fitzgerald, P. B. & Zalesky, A. Functional magnetic resonance imaging–guided personalization of transcranial magnetic stimulation treatment for depression.\n\n*JAMA Psychiatry***78**, 337 (2021).Liao, C., Dua, A. N., Wojtasiewicz, C., Liston, C. & Kwan, A. C. Structural neural plasticity evoked by rapid-acting antidepressant interventions.\n\n*Nat. Rev. Neurosci.***26**, 101–114 (2025).Rasmussen, K. et al. 14. Preclinical pharmacology of DLX-001, a novel non-hallucinogenic neuroplastogen with the potential for treating neuropsychiatric diseases.\n\n*Biol. Psychiatry***95**, S80 (2024).Liu, Y. et al. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189.\n\n*Neuropharmacology***144**, 337–344 (2019).McIntyre, R. S., Johe, K., Rong, C. & Lee, Y. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects.\n\n*Expert Opin. Investig. Drugs***26**, 767–770 (2017).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT06656416](https://clinicaltrials.gov/study/NCT06656416)(2024).Jordan, J. et al. 206. Identification and prospective replication of a cognitive biomarker for predicting the antidepressant effect of ALTO-100, a novel pro-plasticity drug candidate, in patients with major depression: results from a large phase 2a study.\n\n*Biol. Psychiatry***95**, S184 (2024).Alto Neuroscience reports third quarter 2024 financial results and recent business highlights.\n\n*Alto Neuroscience*[https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx](https://investors.altoneuroscience.com/news/news-details/2024/Alto-Neuroscience-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights/default.aspx)(2024).Bizzell, E., Ross, J., Rosenthal, C., Dumont, R. & Schaaf, R. Sensory features as a marker of autism spectrum disorders.\n\n*J. Autism Dev. Disord.***50**, 2240–2246 (2020).Lane, S. J., Reynolds, S. & Dumenci, L. Sensory overresponsivity and anxiety in typically developing children and children with autism and attention deficit hyperactivity disorder: cause or coexistence?\n\n*Am. J. Occup. Ther.***66**, 595–603 (2012).Hudac, C. M. & Webb, S. J. in\n\n*Neurophysiologic Biomarkers in Neuropsychiatric Disorders*:*Etiologic and Treatment Considerations*(eds Javitt, D. C. & McPartland, J. C.) 545–576 (Springer, 2024).Hollander, E. et al. Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial.\n\n*JAMA Psychiatry***79**, 760–769 (2022).Williams, Z. J., Abdelmessih, P. G., Key, A. P. & Woynaroski, T. G. Cortical auditory processing of simple stimuli is altered in autism: a meta-analysis of auditory evoked responses.\n\n*Biol. Psychiatry Cogn. Neurosci. Neuroimaging***6**, 767–781 (2021).Schwartz, S., Shinn-Cunningham, B. & Tager-Flusberg, H. Meta-analysis and systematic review of the literature characterizing auditory mismatch negativity in individuals with autism.\n\n*Neurosci. Biobehav. Rev.***87**, 106–117 (2018).Chien, Y.-L., Hsieh, M. H. & Gau, S. S.-F. Mismatch negativity and P3a in adolescents and young adults with autism spectrum disorders: behavioral correlates and clinical implications.\n\n*J. Autism Dev. Disord.***48**, 1684–1697 (2018).Hudac, C. M. et al. Early enhanced processing and delayed habituation to deviance sounds in autism spectrum disorder.\n\n*Brain Cogn.***123**, 110–119 (2018).Bentin, S., Allison, T., Puce, A., Perez, E. & McCarthy, G. Electrophysiological studies of face perception in humans.\n\n*J. Cogn. Neurosci.***8**, 551–565 (1996).Kala, S. et al. Brief Report: preliminary evidence of the N170 as a biomarker of response to treatment in autism spectrum disorder.\n\n*Front. Psychiatry***12**, 709382 (2021).Mason, L. et al. Stratifying the autistic phenotype using electrophysiological indices of social perception.\n\n*Sci. Transl Med.***14**, eabf8987 (2022).Berry-Kravis, E. M. et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.\n\n*Nat. Med.***27**, 862–870 (2021).US National Library of Medicine.\n\n*ClinicalTrials.gov*[https://clinicaltrials.gov/study/NCT04644003](https://clinicaltrials.gov/study/NCT04644003)(2024).Erickson, C. A. et al. Safety, tolerability, and EEG-based target engagement of STP1 (PDE3,4 inhibitor and NKCC1 antagonist) in a randomized clinical trial in a subgroup of patients with ASD.\n\n*Biomedicines***12**, 1430 (2024).BQP qualification program cover letter.\n\n*FDA*[https://www.fda.gov/media/127495/download](https://www.fda.gov/media/127495/download)(2018).Webb, S. J. et al. The Autism Biomarkers Consortium for Clinical Trials: initial evaluation of a battery of candidate EEG biomarkers.\n\n*Am. J. Psychiatry***180**, 41–49 (2023).McPartland, J. C. et al. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): scientific context, Study Design, and Progress Toward Biomarker Qualification.\n\n*Front. Integr. Neurosci.***14**, 16 (2020).Fox, N. A. et al. The development and structure of the HEALthy Brain and Child Development (HBCD) Study EEG protocol.\n\n*Dev. Cogn. Neurosci.***69**, 101447 (2024).Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products — guidance for industry.\n\n*FDA*[https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products)(2019).*Cancer Drug Approvals Grew from 4% of U.S. Total in the 1980s to 27% in 2010–18*. Impact Report vol. 21 (Tufts Center for the Study of Drug Development, 2019).Pravata, V. M. et al. An intellectual disability syndrome with single-nucleotide variants in O-GlcNAc transferase.\n\n*Eur. J. Hum. Genet.***28**, 706–714 (2020).Roelofs, C. L. et al. Individual alpha frequency proximity associated with repetitive transcranial magnetic stimulation outcome: an independent replication study from the ICON-DB consortium.\n\n*Clin. Neurophysiol.***132**, 643–649 (2021).Ferguson, B. R. & Gao, W.-J. PV Interneurons: critical regulators of E/I balance for prefrontal cortex-dependent behavior and psychiatric disorders.\n\n*Front. Neural Circuits***12**, 37 (2018).Heshmati, M. & Russo, S. J. Anhedonia and the brain reward circuitry in depression.\n\n*Curr. Behav. Neurosci. Rep.***2**, 146–153 (2015).Chaudhury, D. et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons.\n\n*Nature***493**, 532–536 (2013).Tye, K. M. et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour.\n\n*Nature***493**, 537–541 (2013).Su, Y.-A. & Si, T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder.\n\n*Gen. Psychiatry***35**, e100724 (2022).\n\n## Author information\n\n### Authors and Affiliations\n\n### Contributions\n\nThe authors contributed equally to all aspects of the article.\n\n### Corresponding author\n\n## Ethics declarations\n\n### Competing interests\n\nA.E. and P.O. receive salary from Alto Neuroscience. A.E., P.O. and H.M. hold equity in Alto Neuroscience. H.M. holds equity in Johnson & Johnson. He is Scientific Advisory Board member, Board member, strategic adviser and/or consultant (past 5 years) for: Stanley Center, Dana Foundation, Healthy Brains Global Initiative, McLean Hospital, Foundation for OCD, Dolby Family Ventures, Vanna Health, Alto Neuroscience, Noema, Otsuka, Boehringer-Ingelheim, Sanofi, Apollo Therapeutics, Freedom Biosciences, Empyrean, Lundbeck, Psychogenics and Rapport Therapeutics. K.J.R. has performed scientific consultation for Bioxcel, Bionomics, Acer and Jazz Pharma; serves on Scientific Advisory Boards for Sage, Boehringer Ingelheim, Senseye and the Brain Research Foundation; and has received sponsored research support from Alto Neuroscience.\n\n## Peer review\n\n### Peer review information\n\n*Nature Reviews Drug Discovery* thanks Mirko Manchia, Seth Hopkins and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.\n\n## Additional information\n\n**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\n\n## Rights and permissions\n\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\n\n## About this article\n\n### Cite this article\n\nEtkin, A., O’Donnell, P., Ressler, K.J. *et al.* Towards precision psychiatry: initial foundations and future directions.\n*Nat Rev Drug Discov* (2026). https://doi.org/10.1038/s41573-026-01509-0\n\nAccepted:\n\nPublished:\n\nVersion of record:\n\nDOI: https://doi.org/10.1038/s41573-026-01509-0", "url": "https://wpnews.pro/news/towards-precision-psychiatry-initial-foundations-and-future-directions", "canonical_source": "https://www.nature.com/articles/s41573-026-01509-0", "published_at": "2026-08-25 23:26:47+00:00", "updated_at": "2026-08-25 23:44:28.032882+00:00", "lang": "en", "topics": ["artificial-intelligence", "machine-learning", "neural-networks", "ai-research"], "entities": ["Nature Reviews Drug Discovery", "FDA-NIH Biomarker Working Group", "Bristol-Myers", "Tofersen", "Donanemab", "Lecanemab", "Global CEO Initiative on Alzheimer’s Disease", "JAMA Psychiatry"], "alternates": {"html": "https://wpnews.pro/news/towards-precision-psychiatry-initial-foundations-and-future-directions", "markdown": "https://wpnews.pro/news/towards-precision-psychiatry-initial-foundations-and-future-directions.md", "text": "https://wpnews.pro/news/towards-precision-psychiatry-initial-foundations-and-future-directions.txt", "jsonld": "https://wpnews.pro/news/towards-precision-psychiatry-initial-foundations-and-future-directions.jsonld"}}